Table 1. Summary of clinical data and distribution according to the DNA methylation profile.
| Cluster | ||||
| Group I | Group II | |||
| Gender | ||||
| Male | 63 | 31 | 32 | |
| Female | 53 | 27 | 26 | |
| Age | ||||
| <60 yr | 31 | 15 | 16 | |
| >60yr | 85 | 43 | 42 | |
| FAB Sub-type | p* = 0.011 | |||
| M0 | 4 | 3(75%) | 1(25%) | |
| M1 | 19 | 13(68%) | 6(32%) | |
| M2 | 30 | 16(53%) | 14(47%) | |
| M3 | 9 | 0(0%) | 9(100%) | |
| M4 | 13 | 8(61%) | 5(39%) | |
| M4EO | 11 | 5(45%) | 6(55%) | |
| M5 | 27 | 10(37%) | 17(63%) | |
| M6 | 3 | 3(100%) | 0(0%) | |
| TOTAL | 116 | 58(50%) | 58(50%) | |
| Cytogenetic Prognosis Group ** | p*<0.001 | |||
| Favorable | 30 | 6(20%) | 24(80%) | |
| t(8;21) | 10 | 1(10%) | 9(90%) | |
| inv(16) | 11 | 5(45%) | 6(55%) | |
| t(15;17) | 9 | 0(0%) | 9(100%) | |
| Intermediate | 61 | 32(52%) | 29(48%) | |
| Normal Karyotype | 41 | 23(56%) | 18(44%) | |
| Single Trisomy | 12 | 5(42%) | 7(68%) | |
| Double Trisomy | 3 | 2(67%) | 1(33%) | |
| Other Intermediate | 5 | 2(40%) | 3(60%) | |
| Adverse | 25 | 20(80%) | 5(20%) | |
| Complex Karyotype | 14 | 14(100%) | 0(0%) | |
| MLL | 7 | 2(29%) | 5(71%) | |
| Other Adverse | 4 | 4(100%) | 0(0%) | |
| FLT3 | p* = 0.537 | |||
| ITD | 15 | 9(60%) | 6(40%) | |
| Mutation | 6 | 2(33%) | 4(67%) | |
| ITD+Mutation | 1 | 1(100%) | 0(0%) | |
| Negative | 61 | 35(57%) | 26(43%) | |
| ND | 33 | 11(33%) | 22(67%) | |
*p value from Fisher-Freeman-Halton exact test.
**Samples were analyzed cytogenetically according to standard methods and were sub-classified into three sub-groups according to the CALGB cytogenetics cumulative incidence of relapse classification system [39]. The Fisher-Freeman-Halton exact test was calculated for the three major groups (favorable, intermediate, and adverse).